Hosted on MSN28d
Shionogi's RSV antiviral shows promise in hVIVO trial
LONDON - Shionogi & Co., Ltd. (TYO ... oral antiviral candidate targeting Respiratory Syncytial Virus (RSV), conducted by hVIVO plc, a leader in human challenge clinical trials.
2 Minute Medicine10d
Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients
RSV patients treated with antiviral drug S-337395 showed statistically significant reduction in viral load S-337395 is ...
London South East29d
Shionogi reports positive RSV trial results
The trial demonstrated a significant reduction in viral load for Shionogi's investigational oral RSV antiviral candidate, S-337395. S-337395, which has received Fast Track designation from the U.S ...
pharmaphorum7d
Shionogi agrees $140m deal to buy antibiotic biotech Qpex
While most pharma companies have exited the antibiotics area, Japanese drugmaker Shionogi has stuck with it and has just expanded its pipeline with a deal to buy US biotech Qpex Biopharma.
Business Wire1mon
Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder
OSAKA, Japan & SACRAMENTO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, PhD.; hereinafter “Shionogi ...
Investing29d
Shionogi's RSV antiviral shows promise in hVIVO trial
LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...
London South East29d
hVIVO reports positive results from Shionogi RSV trial
(Sharecast News) - hVIVO reported positive results from a phase 2a respiratory syncytial virus (RSV) human challenge trial conducted on behalf of Shionogi on Wednesday. The AIM-traded firm said ...